Companies Regeneron Pharmaceuticals, Inc

Regeneron Pharmaceuticals (REGN): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Regeneron Pharmaceuticals, Inc’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$7,280,549CEO Leonard Schleifer · source

Say-on-pay support93.33%Latest vote · source

CEO vs. named peers1st pct.Of 11 peer CEOs

CEO pay ratio42:1To the median employee · source

CEO pay, last three years

$8,184,338FY2023
$6,823,034FY2024
$7,280,549FY2025

CEO total pay was $7,280,549 in fiscal 2025, up from $6,823,034 in fiscal 2024.

FY2025: salary $1,979,922 · bonus $0

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Regeneron Pharmaceuticals, Inc in fiscal 2025?

As disclosed, Daniel Van Plew (Executive Vice President and General Manager, Industrial Operations and Product Supply) was the highest-paid executive at Regeneron Pharmaceuticals, Inc in fiscal 2025, with total compensation of $8,780,263.

How does Regeneron Pharmaceuticals, Inc's chief executive pay compare to its disclosed peer group?

As disclosed, Leonard Schleifer's total compensation ranked at the 1st percentile of Regeneron Pharmaceuticals, Inc's disclosed peer group.

What is Regeneron Pharmaceuticals, Inc's CEO-to-median employee pay ratio?

As disclosed, Regeneron Pharmaceuticals, Inc's CEO-to-median employee pay ratio was 42:1.

How did shareholders vote on Regeneron Pharmaceuticals, Inc's executive compensation?

As disclosed, 93.33% of shareholders supported Regeneron Pharmaceuticals, Inc's executive compensation in the latest say-on-pay vote.

How much does Regeneron Pharmaceuticals, Inc spend in total on board compensation for fiscal 2025?

As disclosed, Regeneron Pharmaceuticals, Inc reported total board compensation of $2,655,946 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Daniel Van Plew	$983,382	$0	$2,699,728	$4,049,757	$965,189	$0	$82,207	$8,780,263
Executive Vice President and General Manager, Industrial Operations and Product Supply
Andrew Murphy	819,672	0	2,699,728	4,049,757	815,164	0	92,798	8,477,119
Executive Vice President, Co-Chief Scientific Officer
Joseph LaRosa	916,062	1,000,000	1,799,334	2,699,810	911,024	0	132,740	7,458,970
Executive Vice President, General Counsel and Secretary
Leonard Schleifer	1,979,922	0	—	—	3,682,655	0	1,617,972	7,280,549
Board co-Chair, President and Chief Executive Officer
Christopher Fenimore	725,000	0	2,199,751	3,299,977	721,013	0	39,623	6,985,364
Executive Vice President, Finance and Chief Financial Officer
George Yancopoulos	1,979,922	0	—	—	3,682,655	0	1,286,892	6,949,469
Board co-Chair, President and Chief Scientific Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
Daniel Van Plew	$8,780,263	$8,655,178	$8,760,149	↑ +125,085
Andrew Murphy	8,477,119	8,363,257	8,429,311	↑ +113,862
Joseph LaRosa	7,458,970	—	—	—
Leonard Schleifer	7,280,549	6,823,034	8,184,338	↑ +457,515
Christopher Fenimore	6,985,364	6,268,252	—	↑ +717,112
George Yancopoulos	6,949,469	6,796,783	7,759,830	↑ +152,686

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The starting premise for compensation at Regeneron is that our compensation practices must be "fit for purpose" and reinforce the long-term outlook necessary to fulfill the Company's mission - to turn rigorous scientific research into groundbreaking medicines. This mission is the ultimate driver of sustainable, long-term value creation for our shareholders.

CEO STI target (% of salary)	120%
CEO LTI target (% of salary)	—
Independent consultant	Pay Governance LLC
Clawback policy	True
Anti-hedging	True
Anti-pledging	True

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Andrew Murphy	RSU	2025-12-05	—	—	3,715	—	$2,699,728
Andrew Murphy	OPTION	2025-12-05	—	—	18,315	—	4,049,757
Christopher Fenimore	OPTION	2025-12-05	—	—	14,924	—	3,299,977
Daniel Van Plew	RSU	2025-12-05	—	—	3,715	—	2,699,728
Joseph LaRosa	RSU	2025-12-05	—	—	2,476	—	1,799,334
Daniel Van Plew	OPTION	2025-12-05	—	—	18,315	—	4,049,757
Christopher Fenimore	RSU	2025-12-05	—	—	3,027	—	2,199,751
Joseph LaRosa	OPTION	2025-12-05	—	—	12,210	—	2,699,810

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Andrew Murphy	$2,699,728	$0	$4,049,757	0.0%
Christopher Fenimore	2,199,751	0	3,299,977	0.0%
Daniel Van Plew	2,699,728	0	4,049,757	0.0%
Joseph LaRosa	1,799,334	0	2,699,810	0.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Christopher Fenimore	RSU	963	—	$743,311
Joseph LaRosa	RSU	1,066	—	822,813
Christopher Fenimore	RSU	1,185	—	914,666
Joseph LaRosa	RSU	1,376	—	1,062,093
Christopher Fenimore	RSU	1,599	—	1,234,220
Andrew Murphy	RSU	1,599	—	1,234,220
Christopher Fenimore	RSU	1,899	—	1,465,781
Andrew Murphy	RSU	2,064	—	1,593,140
Joseph LaRosa	RSU	2,332	—	1,800,001
Joseph LaRosa	RSU	2,476	—	1,911,150
Christopher Fenimore	RSU	2,591	—	1,999,915
Christopher Fenimore	RSU	3,027	—	2,336,450
Christopher Fenimore	RSU	3,499	—	2,700,773
Andrew Murphy	RSU	3,499	—	2,700,773
Christopher Fenimore	RSU	3,715	—	2,867,497
Andrew Murphy	RSU	3,715	—	2,867,497
Joseph LaRosa	PSU	7,250	—	5,596,057
Christopher Fenimore	PSU	7,766	—	5,994,342
Christopher Fenimore	PSU	10,712	—	8,268,271
Andrew Murphy	PSU	10,877	—	8,395,630

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Christine A. PoonIndependent · Lead Independent Director · Compensation Committee (Chair) · Corporate Governance and Compliance Committee	$170,000	$119,415	$480,552	—	$5,449	$775,416
Michael S. BrownIndependent · Technology Committee	120,000	119,415	480,552	—	10,449	730,416
George L. SingIndependent · Audit Committee (Chair)	120,000	119,415	480,552	—	10,449	730,416
Arthur F. RyanIndependent · Audit Committee	120,000	119,415	480,552	—	5,449	725,416
Huda Y. ZoghbiIndependent · Technology Committee	110,000	119,415	480,552	—	10,449	720,416
N. Anthony ColesIndependent · Audit Committee · Compensation Committee	107,411	119,415	480,552	—	10,449	717,827
Joseph L. GoldsteinIndependent · Corporate Governance and Compliance Committee · Technology Committee	110,000	119,415	480,552	—	5,449	715,416
Bonnie L. BasslerIndependent · Technology Committee	110,000	119,415	480,552	—	5,449	715,416
Craig B. ThompsonIndependent · Corporate Governance and Compliance Committee	103,021	119,415	480,552	—	2,182	705,170
David P. SchenkeinIndependent · Compensation Committee	103,021	119,415	480,552	—	1,577	704,565
Kathryn GuariniIndependent · Audit Committee	100,000	119,415	480,552	—	1,577	701,544
George D. YancopoulosEmployee director	0	0	0	0	0	0
Leonard S. SchleiferEmployee director	0	0	0	0	0	0

Board fee structure and ownership guideline

Annual cash retainer	$90,000
Annual equity retainer	$600,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	10,000 / 10,000 / 10,000
Stock ownership guideline	$1,950,000

Total cost of the board

Component	FY2025
Cash retainers and fees	$1,273,453
Equity awards (grant-date value)	$1,313,565
All other compensation	$68,928
Total cost of the board	$2,655,946

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Regeneron Pharmaceuticals as a peer

Companies that benchmark against REGN

20 companies name REGN as a compensation peer

ALNYLAM PHARMACEUTICALS, INC.ALNYFY2025
AMGEN INCAMGNFY2025
BeOne Medicines Ltd.ONCFY2025
BIOGEN INC.BIIBFY2025
BIOMARIN PHARMACEUTICAL INCBMRNFY2025
BRISTOL MYERS SQUIBB COBMYFY2025
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRLFY2025
CVS HEALTH CorpCVSFY2025
EXELIXIS, INC.EXELFY2025
GILEAD SCIENCES, INC.GILDFY2025
ILLUMINA, INC.ILMNFY2025
INTUITIVE SURGICAL INCISRGFY2025
IQVIA HOLDINGS INC.IQVFY2025
Jazz Pharmaceuticals plcJAZZFY2025
Moderna, Inc.MRNAFY2025
Organon & Co.OGNFY2025
Royalty Pharma plcRPRXFY2025
STRYKER CORPSYKFY2025
UNITED THERAPEUTICS CorpUTHRFY2025
Viatris IncVTRSFY2025

Each company listed discloses REGN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named REGN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

VRTX Vertex Pharmaceuticals IncorporatedALNY Alnylam Pharmaceuticals, Inc.BMY Bristol-Myers Squibb CompanyGILD Gilead Sciences, Inc.ABBV AbbVie Inc.BMRN BioMarin Pharmaceutical Inc.AMGN Amgen Inc.MRK Merck & Co., Inc.BIIB Biogen Inc.LLY Eli Lilly and CompanyINCY Incyte Corporation

Peer reciprocity

The companies Regeneron Pharmaceuticals, Inc names as compensation peers that name it back in their own disclosed peer groups.

Alnylam Pharmaceuticals, Inc. (ALNY)¹⁶³Bristol-Myers Squibb Company (BMY)¹⁶⁴Gilead Sciences, Inc. (GILD)¹⁶⁵BioMarin Pharmaceutical Inc. (BMRN)¹⁶⁶Amgen Inc. (AMGN)¹⁶⁷

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Eli Lilly and Company	2025	David Ricks	$1,700,000	$23,325,000	$0	$6,485,500	$36,698,337
2	AbbVie Inc.	2025	Robert Michael	1,700,000	13,268,456	3,199,154	5,200,000	32,530,984
3	Incyte Corporation	2025	William Meury	647,260	27,509,657	2,573,998	1,300,000	32,085,952
4	Gilead Sciences, Inc.	2025	Daniel O'Day	1,795,192	15,238,402	4,500,060	4,848,120	28,437,198
5	Amgen Inc.	2025	Robert Bradway	1,925,409	12,599,589	5,399,996	3,907,000	24,693,120
6	Biogen Inc.	2025	Christopher Viehbacher	1,727,885	18,368,875	0	3,190,875	23,646,004
7	BioMarin Pharmaceutical Inc.	2025	Alexander Hardy	1,130,769	16,833,629	1,909,310	1,644,500	21,927,563
8	Bristol-Myers Squibb Company	2025	Christopher Boerner	1,586,346	16,061,399	0	3,754,684	21,879,919
9	Vertex Pharmaceuticals Incorporated	2025	Reshma Kewalramani	1,600,000	15,002,270	0	4,118,640	21,144,261
10	Merck & Co., Inc.	2025	Robert Davis	1,645,302	12,102,838	3,380,004	2,326,500	20,797,845
11	Alnylam Pharmaceuticals, Inc.	2025	Yvonne Greenstreet	1,404,200	5,512,500	4,363,380	3,562,500	14,867,600
12	Regeneron Pharmaceuticals, Inc	2025	Leonard Schleifer	1,979,922	—	—	3,682,655	7,280,549

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Regeneron Pharmaceuticals, Inc	155%	Options 60 · RSU 40	not disclosed	Pay Governance LLC
AbbVie Inc.	not disclosed	PSU 40 · PRSU 40 · Option 20	Yes — Relative TSR	Semler Brossy
Alnylam Pharmaceuticals, Inc.	200%	PSU 50 · RSU 25 · Option 25	No	Pay Governance
Amgen Inc.	136.0%	PSU 50 · Options 30 · RSU 20	Yes — relative TSR	Frederic W. Cook & Co., Inc. (FW Cook)
Biogen Inc.	127%	PSU 60 · RSU 40	Yes	Pay Governance
BioMarin Pharmaceutical Inc.	130%	PSU 66 · RSU 21 · Options 13	Yes — Relative TSR	Aon Human Capital Solutions
Bristol-Myers Squibb Company	157.66%	PSU 60 · MSU 40	Yes — 3-Year Relative TSR CAGR	Farient Advisors LLC
Eli Lilly and Company	218%	PSU 100	No	FW Cook
Gilead Sciences, Inc.	180%	PSU 50 · Option 25 · RSU 25	Yes — Relative TSR	FW Cook
Incyte Corporation	138.6%	PSU 60 · RSU 20 · Option 20	Yes — relative total shareholder return (TSR)	Aon
Merck & Co., Inc.	94%	PSU 60 · RSU 20 · Options 20	Yes — Relative Total Shareholder Return (R-TSR)	FW Cook
Vertex Pharmaceuticals Incorporated	not disclosed	PSU 55 · RSU 45	No	Pearl Meyer

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-06-12	96,469,374	6,898,268	105,512	93.33%	Passed
2025	2025-06-13	98,781,758	7,100,590	111,931	93.29%	Passed
2024	2024-06-14	106,667,264	5,579,814	207,463	95.03%	Passed
2023	2023-06-09	97,786,842	14,490,406	240,046	87.09%	Passed
2022	2022-06-10	97,837,229	13,595,339	169,288	87.8%	Passed
2020	2020-06-12	81,690,302	34,709,497	100,771	70.18%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-06-12	93.33%^a
2025	2025-06-13	93.29%^b
2024	2024-06-14	95.03%^c

a. Approved under the standard stated in the filing — “Proposal No. 3: Say-on-Pay Non-binding, advisory proposal. We will consider the matter approved if it receives the affirmative vote of a majority of the votes cast. No effect - not considered votes cast on this proposal No - brokers without voting instructions will not be able to vote on this proposal”.

b. Approved under the standard stated in the filing — “Proposal No. 3: Say-on-Pay -- Non-binding, advisory proposal. We will consider the matter approved if it receives the affirmative vote of a majority of the votes cast | Abstentions: No effect – not considered votes cast on this proposal”.

c. Approved under the standard stated in the filing — “Non-binding, advisory proposal. We will consider the matter approved if it receives the affirmative vote of a majority of the votes cast | Abstentions: No effect – not considered votes cast on this proposal”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	42 : 1
CEO total compensation	$7,280,549
Median employee compensation	$174,138

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Arthur F. Ryan	Director	2026-05-01	D	2	$714	$1,428	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	2	711	1,422	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	6	709	4,257	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	4	707	2,830	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	7	707	4,947	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	14	706	9,878	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	15	704	10,564	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	24	703	16,883	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	15	702	10,537	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	5	702	3,509	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	1	712	712	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	5	711	3,557	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-07-02	D	200	650	130,030	Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-08-10	D	800	800	640,000	Common	Form 4 ↗
Kathryn Guarini	Director	2026-08-10	A	400	719	287,748	Common	Form 4 ↗
Dividend-equivalent accruals		2026-08-10	—	1,200	—	—	2 insiders, 2 accrual rows
Huda Y. Zoghbi	Director	2026-08-10	A	800	377	301,352	Common	Form 4 ↗
Kathryn Guarini	Director	2026-08-10	D	400	800	320,000	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-08-18	A	6,283	382	2,399,603	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-08-18	D	4,599	813	3,741,149	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-08-18	D	6,283	0	0	Derivative, Class A Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-08-19	A	12,282	382	4,690,741	Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-08-19	D	12,282	0	0	Derivative, Class A Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-08-19	D	9,019	830	7,487,123	Common	Form 4 ↗
Marion McCourt	EVP Commercial	2026-09-02	D	1,215	850	1,032,750	Common	Form 4 ↗
Kathryn Guarini	Director	2026-09-02	D	400	850	340,000	Common	Form 4 ↗
Kathryn Guarini	Director	2026-09-02	A	400	719	287,748	Common	Form 4 ↗
Dividend-equivalent accruals		2026-09-02	—	400	—	—	1 insider, 1 accrual row
Marion McCourt	EVP Commercial	2026-09-03	D	1,131	857	969,708	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-13	A	17,000	382	6,492,640	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-13	D	17,000	0	0	Derivative, Class A Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-13	D	12,853	755	9,698,617	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	463	781	361,432	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	454	779	353,503	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	38	778	29,555	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	66	776	51,236	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	121	774	93,712	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	211	773	163,010	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	105	768	80,675	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	192	767	147,339	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	271	765	207,421	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	55	763	41,941	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	27	761	20,557	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	74	761	56,288	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	14	760	10,639	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	224	773	173,242	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	12	770	9,242	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	16	758	12,123	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	35	756	26,457	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	6	754	4,523	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	50	781	39,074	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	380	780	296,244	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	376	775	291,573	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	283	772	218,351	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	127	769	97,701	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	279	766	213,845	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	219	764	167,404	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	25	764	19,094	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	24	758	18,196	Common	Form 4 ↗
Dividend-equivalent accruals		2026-10-30	—	2,329	—	—	2 insiders, 2 accrual rows
Kathryn Guarini	Director	2026-10-30	D	400	900	360,000	Common	Form 4 ↗
Kathryn Guarini	Director	2026-10-30	A	400	719	287,748	Common	Form 4 ↗
Marion McCourt	EVP Commercial	2026-10-30	D	1,132	869	984,195	Common	Form 4 ↗
Michael S. Brown	Director	2026-10-30	D	1,929	875	1,687,875	Common	Form 4 ↗
Michael S. Brown	Director	2026-10-30	A	1,929	726	1,400,242	Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-11-02	D	3,939	965	3,802,750	Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-11-02	D	8,686	951	8,256,043	Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-11-02	D	12,283	0	0	Derivative, Class A Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-11-02	D	527	966	509,140	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-11-02	D	15	0	0	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-11-02	D	4,243	951	4,032,972	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-11-02	A	6,000	382	2,291,520	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	7,830	0	0	Derivative, Class A Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	201	971	195,233	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	937	971	909,368	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	3,203	970	3,105,309	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	2,499	969	2,420,481	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	772	967	746,817	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	7,439	0	0	Derivative, Class A Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	7,830	0	0	Derivative, Class A Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	1,040	967	1,005,753	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	1,522	966	1,470,663	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	7,073	965	6,828,133	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	2,670	965	2,575,402	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	4,338	963	4,179,533	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	2,522	963	2,427,702	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	540	962	519,399	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	1,224	961	1,175,738	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	200	970	194,036	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-11-02	D	6,000	0	0	Derivative, Class A Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	A	7,830	377	2,949,483	Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-11-02	A	12,283	382	4,691,123	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	A	7,439	381	2,833,887	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	A	7,830	377	2,949,483	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	218	967	210,749	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-11-03	D	1,054	0	0	Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-11-03	D	7,439	0	0	Derivative, Class A Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-11-03	D	500	971	485,530	Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-11-03	D	6,939	970	6,733,744	Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-11-03	A	7,439	381	2,833,887	Common	Form 4 ↗
Dividend-equivalent accruals		2026-11-04	—	3,883	—	—	1 insider, 3 accrual rows
Jason Pitofsky	SVP Controller	2026-11-04	D	179	951	170,186	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	35	946	33,096	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	108	944	101,976	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	529	944	499,127	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	1,215	942	1,144,907	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	982	942	924,632	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	575	940	540,765	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	439	940	412,471	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	A	905	492	445,260	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	A	1,478	645	952,630	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	A	1,500	727	1,089,795	Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 116 transactions

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Arthur F. Ryan	Director	2026-05-01	D	2	$714	$1,428	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	2	711	1,422	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	6	709	4,257	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	4	707	2,830	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	7	707	4,947	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	14	706	9,878	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	15	704	10,564	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	24	703	16,883	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	15	702	10,537	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	5	702	3,509	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	1	712	712	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-05-01	D	5	711	3,557	Common	Form 4 ↗
Arthur F. Ryan	Director	2026-07-02	D	200	650	130,030	Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-08-10	D	800	800	640,000	Common	Form 4 ↗
Kathryn Guarini	Director	2026-08-10	A	400	719	287,748	Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-08-10	D	800	0	0	Derivative, Class A Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-08-10	A	800	377	301,352	Common	Form 4 ↗
Kathryn Guarini	Director	2026-08-10	D	400	800	320,000	Common	Form 4 ↗
Kathryn Guarini	Director	2026-08-10	D	400	0	0	Derivative, Class A Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-08-18	A	6,283	382	2,399,603	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-08-18	D	4,599	813	3,741,149	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-08-18	D	6,283	0	0	Derivative, Class A Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-08-19	A	12,282	382	4,690,741	Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-08-19	D	12,282	0	0	Derivative, Class A Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-08-19	D	9,019	830	7,487,123	Common	Form 4 ↗
Marion McCourt	EVP Commercial	2026-09-02	D	1,215	850	1,032,750	Common	Form 4 ↗
Kathryn Guarini	Director	2026-09-02	D	400	850	340,000	Common	Form 4 ↗
Kathryn Guarini	Director	2026-09-02	A	400	719	287,748	Common	Form 4 ↗
Kathryn Guarini	Director	2026-09-02	D	400	0	0	Derivative, Class A Common	Form 4 ↗
Marion McCourt	EVP Commercial	2026-09-03	D	1,131	857	969,708	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-13	A	17,000	382	6,492,640	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-13	D	17,000	0	0	Derivative, Class A Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-13	D	12,853	755	9,698,617	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	463	781	361,432	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	454	779	353,503	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	38	778	29,555	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	66	776	51,236	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	121	774	93,712	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	211	773	163,010	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	105	768	80,675	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	192	767	147,339	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	271	765	207,421	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	55	763	41,941	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	27	761	20,557	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	74	761	56,288	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	14	760	10,639	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	224	773	173,242	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	12	770	9,242	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	16	758	12,123	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	35	756	26,457	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	6	754	4,523	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	50	781	39,074	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	380	780	296,244	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	376	775	291,573	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	283	772	218,351	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	127	769	97,701	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	279	766	213,845	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	219	764	167,404	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	25	764	19,094	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-10-14	D	24	758	18,196	Common	Form 4 ↗
Kathryn Guarini	Director	2026-10-30	D	400	0	0	Derivative, Class A Common	Form 4 ↗
Kathryn Guarini	Director	2026-10-30	D	400	900	360,000	Common	Form 4 ↗
Kathryn Guarini	Director	2026-10-30	A	400	719	287,748	Common	Form 4 ↗
Marion McCourt	EVP Commercial	2026-10-30	D	1,132	869	984,195	Common	Form 4 ↗
Michael S. Brown	Director	2026-10-30	D	1,929	0	0	Derivative, Class A Common	Form 4 ↗
Michael S. Brown	Director	2026-10-30	D	1,929	875	1,687,875	Common	Form 4 ↗
Michael S. Brown	Director	2026-10-30	A	1,929	726	1,400,242	Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-11-02	D	3,939	965	3,802,750	Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-11-02	D	8,686	951	8,256,043	Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-11-02	D	12,283	0	0	Derivative, Class A Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-11-02	D	527	966	509,140	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-11-02	D	15	0	0	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-11-02	D	4,243	951	4,032,972	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-11-02	A	6,000	382	2,291,520	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	7,830	0	0	Derivative, Class A Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	201	971	195,233	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	937	971	909,368	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	3,203	970	3,105,309	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	2,499	969	2,420,481	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	772	967	746,817	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	7,439	0	0	Derivative, Class A Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	7,830	0	0	Derivative, Class A Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	1,040	967	1,005,753	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	1,522	966	1,470,663	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	7,073	965	6,828,133	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	2,670	965	2,575,402	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	4,338	963	4,179,533	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	2,522	963	2,427,702	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	540	962	519,399	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	1,224	961	1,175,738	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	D	200	970	194,036	Common	Form 4 ↗
Christopher Fenimore	EVP Finance CFO	2026-11-02	D	6,000	0	0	Derivative, Class A Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	A	7,830	377	2,949,483	Common	Form 4 ↗
Joseph LaRosa	EVP General Counsel and Secret	2026-11-02	A	12,283	382	4,691,123	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	A	7,439	381	2,833,887	Common	Form 4 ↗
George L. Sing	Director	2026-11-02	A	7,830	377	2,949,483	Common	Form 4 ↗
Christine A. Poon	Director	2026-11-02	D	218	967	210,749	Common	Form 4 ↗
Andrew Murphy	Co-Chief Scientific Officer	2026-11-03	D	1,054	0	0	Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-11-03	D	7,439	0	0	Derivative, Class A Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-11-03	D	500	971	485,530	Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-11-03	D	6,939	970	6,733,744	Common	Form 4 ↗
Huda Y. Zoghbi	Director	2026-11-03	A	7,439	381	2,833,887	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	1,500	0	0	Derivative, Class A Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	1,478	0	0	Derivative, Class A Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	905	0	0	Derivative, Class A Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	179	951	170,186	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	35	946	33,096	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	108	944	101,976	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	529	944	499,127	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	1,215	942	1,144,907	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	982	942	924,632	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	575	940	540,765	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	D	439	940	412,471	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	A	905	492	445,260	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	A	1,478	645	952,630	Common	Form 4 ↗
Jason Pitofsky	SVP Controller	2026-11-04	A	1,500	727	1,089,795	Common	Form 4 ↗

Sources (167 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Daniel Van Plew. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 8,780,263. View filing ↗
Section 01, Andrew Murphy. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 8,477,119. View filing ↗
Section 01, Joseph LaRosa. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 7,458,970. View filing ↗
Section 01, Leonard Schleifer. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 7,280,549. View filing ↗
Section 01, Christopher Fenimore. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 6,985,364. View filing ↗
Section 01, George Yancopoulos. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 6,949,469. View filing ↗
Section 03, Andrew Murphy RSU. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Andrew Murphy OPTION. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Christopher Fenimore OPTION. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Daniel Van Plew RSU. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Joseph LaRosa RSU. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Daniel Van Plew OPTION. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Christopher Fenimore RSU. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Joseph LaRosa OPTION. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A, filed 2026-04-24. Section “CEO Pay Ratio”. As printed: 42 : 1. View filing ↗
Section 08, Christine A. Poon. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 775,416. View filing ↗
Section 08, Michael S. Brown. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 730,416. View filing ↗
Section 08, George L. Sing. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 730,416. View filing ↗
Section 08, Arthur F. Ryan. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 725,416. View filing ↗
Section 08, Huda Y. Zoghbi. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 720,416. View filing ↗
Section 08, N. Anthony Coles. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 717,827. View filing ↗
Section 08, Joseph L. Goldstein. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 715,416. View filing ↗
Section 08, Bonnie L. Bassler. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 715,416. View filing ↗
Section 08, Craig B. Thompson. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 705,170. View filing ↗
Section 08, David P. Schenkein. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 704,565. View filing ↗
Section 08, Kathryn Guarini. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 701,544. View filing ↗
Section 08, George D. Yancopoulos. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
Section 08, Leonard S. Schleifer. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Arthur F. Ryan 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Huda Y. Zoghbi 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathryn Guarini 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Huda Y. Zoghbi 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Huda Y. Zoghbi 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathryn Guarini 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathryn Guarini 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher Fenimore 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher Fenimore 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher Fenimore 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph LaRosa 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph LaRosa 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph LaRosa 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marion McCourt 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathryn Guarini 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathryn Guarini 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathryn Guarini 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marion McCourt 2026-09-03. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathryn Guarini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathryn Guarini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kathryn Guarini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Marion McCourt 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael S. Brown 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael S. Brown 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael S. Brown 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph LaRosa 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph LaRosa 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph LaRosa 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph LaRosa 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher Fenimore 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher Fenimore 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher Fenimore 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christopher Fenimore 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph LaRosa 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Andrew Murphy 2026-11-03. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Huda Y. Zoghbi 2026-11-03. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Huda Y. Zoghbi 2026-11-03. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Huda Y. Zoghbi 2026-11-03. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Huda Y. Zoghbi 2026-11-03. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-06-17. Item 5.07 · say-on-pay result. As reported: 93.33% (votes for as printed: 96,469,374). View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-06-18. Item 5.07 · say-on-pay result. As reported: 93.29% (votes for as printed: 98,781,758). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-06-20. Item 5.07 · say-on-pay result. As reported: 95.03% (votes for as printed: 106,667,264). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 1,273,453 + equity 1,313,565 + all other 68,928 = 2,655,946, summed across the director compensation table rows.
Eli Lilly and Company, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. View filing ↗
AbbVie Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. View filing ↗
Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
Gilead Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. View filing ↗
Amgen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. View filing ↗
Biogen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. View filing ↗
BioMarin Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. View filing ↗
Bristol-Myers Squibb Company, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. View filing ↗
Vertex Pharmaceuticals Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. View filing ↗
Merck & Co., Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Merck & Co., Inc.'s own proxy. As printed: 20,797,845. View filing ↗
Alnylam Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. View filing ↗
Regeneron Pharmaceuticals, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Regeneron Pharmaceuticals, Inc's own proxy. As printed: 7,280,549. View filing ↗
Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity. DEF 14A. Alnylam Pharmaceuticals, Inc. names Regeneron Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Bristol-Myers Squibb Company reciprocity. DEF 14A. Bristol-Myers Squibb Company names Regeneron Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Gilead Sciences, Inc. reciprocity. DEF 14A. Gilead Sciences, Inc. names Regeneron Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, BioMarin Pharmaceutical Inc. reciprocity. DEF 14A. BioMarin Pharmaceutical Inc. names Regeneron Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Amgen Inc. reciprocity. DEF 14A. Amgen Inc. names Regeneron Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗